NEW YORK, NY — Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell...

PARIS. France — One Biosciences today announced data showing some ovarian cancer tumor cells are predisposed to resist chemotherapy and single-cell profiling at diagnosis can identify tumor profiles that indicate which patients are likely to experience treatment failure, ultimately enabling more personalized treatment strategies. Researchers from One Biosciences, French National...

NEW YORK, NY — Medicovestor, Inc. today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to MC001, its lead investigational first-in-class chemoimmunotherapy antibody-drug-conjugate (ADC) for pancreatic cancer. The company is preparing to initiate an international, multicenter Phase 1 clinical study evaluating MC001’s safety, tolerability,...